A retrospective study finds that more than one third of patients with stage I-IIIA non-small cell lung cancer do not undergo surgery due to old age, comorbidities, or poorer lung function.

Salvage surgery is feasible for NSCLC patients responding to targeted or immunotherapy, with a 36% pCR rate observed. The study included 30 patients, with 22 receiving immunotherapy and 8 receiving ...

Precision-targeted radiation is proving a match for surgery in early-stage lung cancer, offering patients similar long-term survival with less invasiveness, and potentially transforming how this ...

Adding immunotherapy to chemotherapy before surgery for patients with operable non-small cell lung cancer—the leading cause of cancer deaths worldwide—improved long-term survival overall compared with ...

When appropriate, surgery remains the most effective treatment option for non-small cell lung cancer (NSCLC), including for patients with COPD, said Friedberg, professor in the Department of Thoracic ...

Please provide your email address to receive an email when new articles are posted on . The recurrence-free survival estimate at 5 years was 34% in stage III non-small cell lung cancer. Significant ...

A new study suggests patients who recover slowly from non-small-cell lung cancer (NSCLC) surgery may still benefit from delayed chemotherapy started up to four months after surgery, according to a new ...

Breakthrough research presented at the 2026 Society of Thoracic Surgeons Annual Meeting shows that additional lymph node ...

Multidisciplinary evaluation, including thoracic surgical consultation, is crucial for oligometastatic NSCLC patients to optimize treatment strategies. Lung surgery for oligometastatic NSCLC shows ...

Please provide your email address to receive an email when new articles are posted on . Surgery and stereotactic ablative radiotherapy conferred comparable 10-year survival among patients with ...